Compass Therapeutics (CMPX) stock

Worth $151MShares as of Nov 5

$0.84

+0.13%

As of Tuesday's close · Live for Pro members at the open

Not scored

Breakaway doesn't score CMPX. It is priced too low for a fair Quality Score.

Healthcare · Biotech

NextQ4 2026“…bispecific antibody) have been dosed and the study is actively enrolling, with initial data expected in Q4…”Trial data · SEC filing · Aug 6

Follow CMPX's trial news. Pro members can get an alert when Compass Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when CMPX files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. 3,168 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

What's next for CMPX, and how long its cash lasts

Next step the company has named

Q4 2026“The first patients in the Phase 1 study for CTX-10726 (PD-1 x VEGF-A bispecific antibody) have been dosed and the study is actively enrolling, with initial data expected in Q4.”Trial data · SEC filing · Aug 6

What it means: the first look at a trial’s main results, as the company reports them.

Lead program: CTX-10726 · Gastroesophageal Cancer (GC) · Phase 1
Its trial: Safety and Tolerability of CTX-10726Phase 1 · Recruiting · 70 people · main data estimated Apr 1, 2028 · NCT07419841

3 more trials, 1 with data due this year, 3 more milestones and 28 filings, for Pro members.

Cash runway

The company says its cash lasts into 2028 (8-K, Nov 9).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Dec 30, 2025)
At-the-market share sales program (S-3, filed Dec 30, 2025)

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Chief Accounting Officer Neil Lerner bought 20,000 shares on Oct 1. 3 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Thomas Schuetz buys or sells

For Pro members: every trade, and Thomas Schuetz’s 16 filings and quotes.

Get an alert when CMPX files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

CMPX's latest filings

Quarterly report10-Q, filed Nov 9
Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update8-K, filed Nov 9
An insider's trade or awardForm 4, filed Oct 2

19 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why CMPX isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. CMPX trades at $0.84. A stock that clears every mark is scored from the next weekly rebuild.

Straight AnswersStraight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.